Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by 33c

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $3.22, $0.33 better than the analyst estimate of $2.89. Revenue for the quarter came in at $412 million versus the consensus estimate of $421 million.

GUIDANCE:

Jazz Pharmaceuticals sees FY2017 EPS of $10.70-$11.20, versus the consensus of $10.90. Jazz Pharmaceuticals sees FY2017 revenue of $1.6-1.65 million, versus the consensus of $1.64 million.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Movano (MOVE) Misses Q2 EPS by 195c